Buprenorphine Dosing Frequency is not Associated with Maternal Stability and Neonatal Outcomes

Abstract

specificity of 70% (95%CI 50.6-85.2%) and 86.2% (95%CI 68.3-96.1%) for PAS. PPV and NPV were 84% (95%CI 67.2-93%) and 73.5% (95%CI 61.2-83%), superior to ultrasound and MRI, from previously published data. In addition, VEGF identified 65% (9/14) of patients transfused >4 units of blood, 74% (22/30) with a length of stay >4 days and 65% (9/14) admitted to the ICU. CONCLUSION: In this large cohort, urine VEGF was associated with PAS as well as maternal morbidity. VEGF warrants further evaluation as a biomarker for diagnosis of PAS and prediction of PAS associated morbidity.

Preparation and Synergistic Anti-Tumor Effect of Iridium Oxide Nanocomposites under Microscope

“…Targeted preparation is a carrier preparation that can selectively transport drugs to lesion sites and improve drug utilization. It can reduce the frequency of administration, improve the adaptability of patients, and reduce medical cost [ 5 ]. At present, many drug carriers have been used in the targeted delivery system of chemotherapy drugs.…”